Topic
Sculptra
About: Sculptra is a research topic. Over the lifetime, 37 publications have been published within this topic receiving 995 citations.
Papers
TL;DR: An overview of injectable permanent fillers, including ArteFill, Aquamid, and silicone, and semipermanent filler, including Radiesse, Sculptra, and autologous fat, is presented.
Abstract: The demand for safe, effective, long-lasting, biocompatible dermal filler materials is increasing. Many products that include synthetic polymers and autologous tissue have emerged that attempt to meet these criteria. An overview of injectable permanent fillers, including ArteFill, Aquamid, and silicone, and semipermanent fillers, including Radiesse, Sculptra, and autologous fat, is presented. A discussion of their composition, histologic characteristics, antigenicity, U.S. Food and Drug Administration approval status, indications for use, efficacy, injection technique, and adverse effects is provided.
227 citations
TL;DR: Reconstitution, injection techniques, management, and avoidance of complications are listed to achieve safer, consistent results while minimizing risks of complications with injectable poly-L-lactic acid.
Abstract: Background:Poly-L-lactic acid gained U.S. Food and Drug Administration approval for use in human immunodeficiency virus–related facial lipoatrophy in August of 2004. Since that time, it has become available for use in the United States for human immunodeficiency virus facial lipoatrophy patients and
165 citations
TL;DR: Because of its unique mechanism of action, PLLA for nonsurgical facial rejuvenation requires meticulous injection technique with special considerations for optimizing outcomes and minimizing adverse events.
106 citations
TL;DR: Both the natural method of volume restoration and the persistence of results of up to 2 to 3 years makeculptra one worthy of inclusion in the first line of tools for cosmetic rejuvenation as well as for reconstructive soft tissue deficits and lipoatrophy.
Abstract: Sculptra is a biocompatible, resorbable injectable filler composed of poly-L-lactic acid (PLLA). It falls in the class of a stimulatory filler that creates its effect through encouraging neocollagenesis when injected. As it differs from traditional, static fillers such as hyaluronic acid and collagen, it requires a special understanding of how it works, where it can be used, and how it should be injected. The goal of this article is to review the nature of stimulatory volume replacement with a focus on PLLA and its unique considerations. Both the natural method of volume restoration and the persistence of results of up to 2 to 3 years make this product one worthy of inclusion in the first line of tools for cosmetic rejuvenation as well as for reconstructive soft tissue deficits and lipoatrophy.
78 citations
TL;DR: This article reviews European and U.S. clinical study data and summarizes treatment technique for both on label and off-label use ofculptra in the treatment of lipoatrophy.
Abstract: Sculptra (poly-L-lactic acid) as of August 2004 has been approved by the U.S. Food and Drug Administration as the first injectable facial volumizer in the treatment of lipoatrophy. Lipoatrophy is often seen in HIV-positive patients and is felt to be multi-factorial. This article reviews European and U.S. clinical study data and summarize treatment technique for both on label and off-label use.
53 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2020 | 1 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2012 | 3 |